Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept raises $25 million

This article was originally published in Scrip

Executive Summary

Intercept Pharmaceuticals has raised $25 million in the second tranche of a $41 million financing round, led by Genextra, which began in May 2006. The financing will enable Intercept to complete Phase II clinical trials of its lead compound, the orally available farnesoid X receptor INT-747, of which three are currently underway in patients with primary biliary cirrhosis and diabetic patients with non-alcoholic fatty liver disease. The company said that with the backing of Genextra it will also be able to continue to advance its pipeline of other FXR and TGR5 agonists. In addition to the financing, which exceeded the company's expectations of $20.5 million, Dr Kenneth Noonan, a partner at LEK Consulting, has been appointed non-executive chairman of Intercept's board of directors. He succeeds James Mervis, who remains a director of the company.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC005640

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel